Telomir Pharmaceuticals, Inc. Research and Development Expense
Telomir Pharmaceuticals, Inc. (TELO) reported Research and Development Expense of $444.67 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $444.67K, a 938.01% increase year-over-year.
- Telomir Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $467.80K, a 38.81% increase year-over-year.
- Telomir Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $1.30M, a 381.71% increase year-over-year.
- Telomir Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $759.52K, a 21.05% increase year-over-year.
- Telomir Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $2.44M, a 8.96% increase from fiscal 2024.
- Telomir Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $2.24M, a 41.99% increase from fiscal 2023.
- Telomir Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $1.57M, a 88.95% increase from fiscal 2022.
- Telomir Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $833.21K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $444.67K 10-Q · filed 2026-08-13 | $912.47K 10-Q · filed 2026-08-13 | $2.21M derived: sum of 3 quarters · filed 2026-08-13 | $2.97M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $467.80K 10-Q · filed 2026-05-14 | $1.76M derived: sum of 2 quarters · filed 2026-05-14 | $2.52M derived: sum of 3 quarters · filed 2026-05-14 | $2.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.06M derived: sum of 2 quarters · filed 2026-03-17 | $2.10M derived: sum of 3 quarters · filed 2026-08-13 | $2.44M 10-K · filed 2026-03-17 |
| 2025-09-30 | $759.52K 10-Q · filed 2025-11-10 | $802.36K derived: sum of 2 quarters · filed 2026-08-13 | $1.14M 10-Q · filed 2025-11-10 | $1.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $42.84K 10-Q · filed 2026-08-13 | $379.83K 10-Q · filed 2026-08-13 | $648.92K derived: sum of 3 quarters · filed 2026-08-13 | $1.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $337.00K 10-Q · filed 2026-05-14 | $606.08K derived: sum of 2 quarters · filed 2026-05-14 | $1.23M derived: sum of 3 quarters · filed 2026-05-14 | $1.83M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $269.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $896.52K derived: sum of 2 quarters · filed 2026-03-17 | $1.49M derived: sum of 3 quarters · filed 2026-03-17 | $2.24M 10-K · filed 2026-03-17 |
| 2024-09-30 | $627.43K 10-Q · filed 2025-11-10 | $1.22M derived: sum of 2 quarters · filed 2025-11-10 | $1.97M 10-Q · filed 2025-11-10 | $2.23M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $594.80K 10-Q · filed 2025-08-14 | $1.40M 10-Q · filed 2025-08-14 | $1.60M derived: sum of 3 quarters · filed 2025-08-14 | $1.87M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $804.02K 10-Q · filed 2025-05-14 | $1.01M derived: sum of 2 quarters · filed 2025-05-14 | $1.27M derived: sum of 3 quarters · filed 2025-05-14 | $1.94M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $203.78K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | $466.35K derived: sum of 2 quarters · filed 2025-02-04 | $1.13M derived: sum of 3 quarters · filed 2025-02-04 | $1.57M 10-K · filed 2025-02-04 |
| 2023-09-30 | $262.56K 10-Q · filed 2024-11-12 | $930.19K derived: sum of 2 quarters · filed 2024-11-12 | $1.37M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $667.63K 10-Q · filed 2024-08-13 | $1.11M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $440.33K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $833.21K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |